Scharioth Macula Lens: A new intraocular implant for low-vision patients with stabilized maculopathy-first experience
Abstrakt
Aims. To present the initial results of Scharioth Macula Lens (SML) implantation.
The SML is a new add-on intraocular lens designed to increase uncorrected near visual acuity (UCVA) in patients with stabilized maculopathy. Methods.
Eight patients were included in the study. All met the indication criteria before SML implantation.
An SML was implanted in the better seeing eye. Near and distance visual acuity were tested.
Possible complications and patient complaints were recorded and patients were asked about their quality of vision after SML implantation. The examination was carried out on day 1, 1 week, 1, 3 and 6 months after surgery.
Results. Six-month-results are presented.
Apart from one, all patients with the SML had good near visual acuity at a recommended reading distance of 15 cm. Preoperatively, the mean (min-max) near UCVA was J13 (J8-J16), mean distance BCVA was 0.27.
Postoperatively, the best results were after 1 month - near UCVA was J2.5 (J1-J7), distance BCVA was 0.26. Three months after surgery, this decreased to J4.5 (J1-J8); distance VA remained 0.25.
Six months postoperatively near vision was J4 (J1-J8) and distance VA was unchanged. Patients reported problems with reading speed and reading distance.
Daily exercise improved their reading ability. One patient converted to wet AMD 3 months post-implantation.
Conclusion. The SML is a new hope for low-vision patients.
It acts as a magnifier in the eye. It is a suitable method for increasing near visual acuity in patients with inactive maculopathy.